CL110: Updated Analysis of First-line BR vs FCR in Fit Patients With Chronic Lymphocytic Leukemia

December 3-6, 2016; San Diego, California
Median PFS is improved with FCR vs BR in fit younger patients with CLL, although BR remains an option for fit elderly patients with a lower risk of second primary malignancies.
Format: Microsoft PowerPoint (.ppt)
File Size: 447 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Commentary from Jeff Sharman, MD, on noncovalent BTK inhibitors in patients with CLL and progression on currently available BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: September 25, 2020

Interactive on-demand Webcast featuring expert insights on the newest data influencing best practice for managing patients with CLL

Farrukh T. Awan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 24, 2020 Expired: September 23, 2021

Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Farhad Ravandi, MD, discuss important presentations in hematologic malignancies from the virtual ASCO 2020 as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji Kumar, MD Farhad Ravandi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 23, 2020 Expired: September 22, 2021

Commentary by Jesús F. San-Miguel, MD, PhD, on treating patients with myeloma who experience biochemical relapse from Clinical Care Options (CCO)

Jesús F. San-Miguel, MD, PhD Released: September 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue